Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors

HIGHLIGHTS
Hispanics/Latinxs (HL) had worse COVID-19 outcomes than Non-HL whites (NHL-W)

The worse HL outcomes remained after correcting for common comorbid risk factors

Most risk factors were shared, but mitral valve disorder was only a risk in HL

Hospitalized HL presented with a greater inflammatory response
Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors

Timothy S. Chang,1,13,* Yi Ding,2,3,13 Malika K. Freund,3,4,13 Ruth Johnson,3,5,13 Tommer Schwarz,2,3,13 Julie M. Yabu,6 Chad Hazlett,7,8 Jeffrey N. Chiang,9 David A. Wulf,7 UCLA Precision Health Data Discovery Repository Working Group, Daniel H. Geschwind,1,4,10 Manish J. Butte,11,12,* and Bogdan Pasaniuc2,3,4,9,14,*

SUMMARY
Coronavirus disease 2019 (COVID-19) has exposed health care disparities in minority groups including Hispanics/Latinxs (HL). Studies of COVID-19 risk factors for HL have relied on county-level data. We investigated COVID-19 risk factors in HL using individual-level, electronic health records in a Los Angeles health system between March 9, 2020, and August 31, 2020. Of 9,287 HL tested for SARS-CoV-2, 562 were positive. HL constituted an increasing percentage of all COVID-19 positive individuals as disease severity escalated. Multiple risk factors identified in Non-Hispanic/Latinx whites (NHL-W), like renal disease, also conveyed risk in HL. Pre-existing nonrheumatic mitral valve disorder was a risk factor for HL hospitalization but not for NHL-W COVID-19 or HL influenza hospitalization, suggesting it may be a specific HL COVID-19 risk. Admission laboratory values also suggested that HL presented with a greater inflammatory response. COVID-19 risk factors for HL can help guide equitable government policies and identify at-risk populations.

INTRODUCTION
While still in the midst of the coronavirus disease 2019 (COVID-19) pandemic (Center for Systems Science and Engineering at Johns Hopkins University, 2020, Centers for Disease Control and Prevention, 2020, The Lancet, 2020), knowledge of risk factors associated with COVID-19 susceptibility and severity can shape government policies, identify at-risk populations, guide clinical decision-making, and prioritize future COVID-19 research. COVID-19 has further exposed health care disparities exacting a greater toll on minority groups including Hispanic or Latinx communities. COVID-19 diagnosis rates are greater in US counties with a high Latinx proportion compared with those with a low Latinx proportion (91 vs 82 per 100,000) (Rodriguez-Diaz et al., 2020). The Los Angeles County of Public Health data showed the age-adjusted rate of COVID-19 cases is 113 per 100,000 individuals self-reporting as Hispanics/Latinxs (HL) but only 78 for individuals self-reporting as Non-Hispanic/Latinx whites (NHL-W) (Los Angeles County Department of Public Health, Chief Science Office, 2020). Similar findings have been reported by the New York City Health Department and Chicago Department of Public Health where the rates of COVID-19 cases and severe outcomes are roughly twice as high in HL when compared with whites (Chicago Department of Public Health, 2020; New York City Health, 2020). Linking county or zip code level data with aggregate patient data has shed light on conditions that may explain the higher risk of HL COVID-19 cases and disease severity. Many HL individuals work in the service industry (US Bureau of Labor Statistics, 2019), live in densely populated neighborhoods, and have limited access to both open spaces and nearby supermarkets (Ong et al., 2020; Rodriguez-Diaz et al., 2020). Counties with more monolingual Spanish speakers, higher unemployment rates, and air pollution were associated with higher COVID-19 cases (Rodriguez-Diaz et al., 2020). Less medical coverage and higher rates of comorbidities such as diabetes, cardiovascular disease, and renal disease in HL may contribute as well (Cheng et al., 2019; Rodriguez-Diaz et al., 2020; US Department of Health and Human Services, 2018).
There are limited studies investigating HL characteristics for COVID-19 diagnosis and severe outcomes using individual-level data. In a Providence, Rhode Island, study of HL with COVID-19, 75% were younger than 50 years (Weng et al., 2020). In Baltimore, Maryland, hospitalized HL individuals were younger and had lower rates of comorbidities (hypertension, congestive heart failure, chronic obstructive pulmonary disease) compared with hospitalized non-HL white individuals (Martinez et al., 2020). No previous study using individual-level data has investigated the risk factors for COVID-19 diagnosis, inpatient admission, or severe outcome in HL individuals.

In this retrospective study, we aimed to first validate the extendibility of known risk factors for COVID-19 and to determine whether there were pre-existing risk factors observed in HL, but not NHL-W for COVID-19 diagnosis susceptibility, inpatient admission, and severe outcome. We leveraged individual, patient-level, de-identified electronic health record data from the University of California Los Angeles (UCLA) Health System, a single homogeneous medical system. Although many previously identified risk factors were observed in both HL and NHL-W, we identified COVID-19 risk factors that were observed in HL, but not NHL-W. Individuals with numerous pre-existing conditions may be in a general state of poor health, conferring a high risk of hospitalization for any infection, not just COVID-19. To test the hypothesis that certain pre-existing conditions offer a specific risk for COVID-19, we determined if inpatient risk factors for COVID-19 were also inpatient risk factors for influenza.

**RESULTS**

**Study subjects**

The UCLA Health System includes two hospitals (520 and 281 inpatient beds) and 210 primary and specialty outpatient locations predominantly within Los Angeles County. We leveraged an extract of the de-identified electronic health records from the UCLA Health System known as the Data Discovery Repository, which contains longitudinal records for more than 1.5 million patients since 2013.

This retrospective analysis included individuals who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via reverse-transcriptase polymerase chain reaction (RT-PCR) within the UCLA Health System between March 9, 2020, and August 31, 2020. Of the 58,901 individuals PCR-tested for SARS-CoV-2 (Tested) meeting inclusion/exclusion criteria (Methods), 1,994 were COVID-19 positive (3.3% of Tested), 342 were admitted in the hospital (Inpatient) (17% of COVID-19 positive), and 74 were treated in the intensive care unit or required intubation (Severe) (3.7% of COVID-19 positive) (Figure 1).

To determine pre-existing conditions and medications associated with COVID-19 outcome in HL, we included HL individuals self-identifying as HL ethnicity and any race. We included all race groups, not only white, as many HL individuals self-identify as “other race” (52% of HL COVID-19 Tested). We analyzed diagnoses entered in the electronic health record (EHR) before an individual’s SARS-CoV-2 test. International Statistical Classification of Diseases codes were mapped to ~1,800 phecodes, which have been...
shown to represent meaningful and interpretable phenotypes (Wei et al., 2017). We compared risk factors in HL with COVID-19 outcome risk factors in NHL-W, which has been the study population for many previous analyses (Argenziano et al., 2020; Goyal et al., 2020; Grasselli et al., 2020a; Hirsch et al., 2020; Lighter et al., 2020; Williamson et al., 2020). Of the 1,994 COVID-19 positive individuals, 562 were HL and 679 were NHL-W. Of the 342 COVID-19 positive inpatients, 132 were HL and 125 were NHL-W. Of the 74 COVID-19 positive inpatient severe group, 35 were HL and 19 were NHL-W (Figure 1).

We sought COVID-19 susceptibility risk factors by comparing the COVID-19 positive group with the COVID-19 negative group, inpatient risk factors by comparing the COVID-19 positive inpatient group with the COVID-19 positive outpatient group, and severe risk factors by comparing the COVID-19 positive inpatient severe group with the COVID-19 positive inpatient not severe group.

HL have worse COVID-19 outcomes

Compared with all tested individuals, COVID-19 positive individuals were significantly more likely to be male (48% male COVID-19 positive vs 45% male Tested; odds ratio OR = 1.2 [1.1, 1.3]; p = 0.002). Compared with COVID-19 positive individuals, inpatients were more likely to be older than 65 years (50% > 65 years old Inpatient versus 18% > 65 years old COVID-19 positive; OR = 8.1 [6.3, 11]; p < 0.001) (Table 1). These findings confirm in this population that males and older individuals face higher risks of severe disease (Chicago Department of Public Health, 2020; Los Angeles County Department of Public Health, Chief Science Office, 2020; New York City Health, 2020).

Self-identified HL individuals constituted an increasing percentage of COVID-19 individuals as disease severity escalated. HL comprised 15% of the Tested population, whereas they comprised 28% of COVID-19 positive individuals (28% COVID-19 positive versus 15% Tested; OR = 2.1 [1.9, 2.3]; p < 0.001), 38% of inpatient individuals (38% Inpatient versus 28% COVID-19 positive; OR = 2.8 [2.1, 3.8]; p < 0.001), and 47% of Severe individuals (47% Severe versus 38% COVID-19 positive; OR = 1.4 [0.8, 2.5]; p = 0.18).

|Demographic| Severe (N = 74) | Inpatient (N = 342) |COVID-19 positive (N = 1994) | Tested (N = 58,901) |
|---|---|---|---|---|
|Age group| | | | |
|<18 years| 4 (5%) | 10 (2%) † | 112 (5%) † | 4,119 (6%) |
|19–35 years| 7 (9%) | 34 (9%) † | 601 (30%) † | 12,281 (20%) |
|36–50 years| 11 (14%) | 46 (13%) † | 485 (24%) † | 13,046 (22%) |
|51–65 years| 23 (31%) | 78 (22%) | 436 (21%) † | 15,236 (25%) |
|>65 years| 29 (39%) † | 174 (50%) † | 360 (18%) † | 14,219 (24%) |
|Sex| | | | |
|Female| 35 (47%) | 159 (46%) | 1,021 (51%) † | 32,193 (54%) |
|Male| 39 (52%) | 183 (53%) | 973 (48%) † | 26,708 (45%) |
|Race| | | | |
|White or Caucasian| 32 (43%) | 171 (50%) | 908 (45%) † | 33,997 (57%) |
|Black or African American| 10 (13%) | 33 (9%) | 166 (8%) † | 3,611 (6%) |
|Asian| 4 (5%) | 24 (7%) | 118 (5%) † | 5,137 (8%) |
|American Indian or Alaska Native| 0 (0%) | 0 (0%) | 8 (0%) | 218 (0%) |
|Native Hawaiian or other Pacific Islander| 0 (0%) | 0 (0%) | 2 (0%) | 132 (0%) |
|Other race| 28 (37%) | 108 (31%) † | 490 (24%) † | 9,695 (16%) |
|Unknown race| 0 (0%) | 6 (1%) † | 302 (15%) † | 6,111 (10%) |
|Ethnicity| | | | |
|Hispanic or Latinx| 35 (47%) | 132 (38%) † | 562 (28%) | 9,287 (15%) |
|Not Hispanic or Latinx| 38 (51%) | 203 (59%) | 1,134 (56%) † | 43,227 (73%) |
|Unknown ethnicity| 1 (1%) | 7 (2%) | 298 (14%) | 6,387 (10%) |

Table 1. Demographics of COVID-19 patient groups

[(†)] indicates a statistically significant negative/positive association (p < 0.05) of the demographic and two patient groups. For age group and sex, percentage of Severe was compared with Inpatient, Inpatient was compared with COVID-19 positive, and COVID-19 positive was compared with Tested. Significant association of race and ethnicity for Severe compared Inpatient Severe versus Inpatient Not Severe, for Inpatient compared COVID-19 positive Inpatient versus COVID-19 positive Outpatient, and for COVID-19 positive compared COVID-19 positive versus COVID-19 negative while controlling for age group and sex.
These findings show that HL had a higher risk of testing positive, and that when positive, suffered from more severe COVID-19 disease. To evaluate if comorbidities contributed to disproportionate COVID-19 disease outcomes in HL compared with NHL-W, we next corrected for patient histories of known COVID-19 risk factors such as type 2 diabetes, hyperlipidemia, hypertension, and chronic renal disease (Methods and Table S1), many of which are known to disproportionately affect HL individuals (Dominguez et al., 2015; Velasco-Mondragon et al., 2016). After correction for these known risk factors, the odds ratio for having a positive test remained >2.5 in HL, and for being hospitalized remained >2.5 in HL (Tables 2 and S2). These findings support the hypothesis of HL-specific risk factors (medical and/or socioeconomic) that increase the risk of having COVID-19 disease and being hospitalized (Ong et al., 2020).

Pre-existing conditions in HL that are risk factors for testing COVID-19 positive

COVID-19 risk factors (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease [Goyal et al., 2020; Grasselli et al., 2020a; 2020b; Guan et al., 2020; Gupta et al., 2020; Li et al., 2020; Yang et al., 2020a; Zhou et al., 2020a; Zhu et al., 2020]) have been previously identified primarily from COVID-19 inpatient cohorts and white or Asian populations. By grouping phecodes into these known risk factor categories (Table S1), we determined if these were also risk factors in HL while controlling for age and sex. For COVID-19 diagnosis susceptibility, none of these known risk factors were significant in HL. In NHL-W, congestive heart failure (OR 1.7 [1.2–2.3], p = 0.001) and diabetes (OR 1.4 [1.1–1.7], p = 0.02) were COVID-19 susceptibility risk factors, whereas hyperlipidemia was protective (OR 0.69 [0.57–0.84], p = 1.6×10⁻¹⁰) (Figure 2).

To identify additional pre-existing conditions aside from known risk factors that may be COVID-19 susceptibility risk factors in HL, we evaluated all phecodes while controlling for age and sex. In HL, we did not identify any additional phecodes associated with COVID-19 diagnosis susceptibility after multiple testing correction (Methods). In contrast for NHL-W, dementia (OR 4.1 [2.7–6.1], p = 3.4×10⁻⁶), diastolic heart failure (OR 3.0 [1.9–4.4], p = 5.2×10⁻⁴), and fever of unknown origin (OR 2.0 [1.6–2.4], p = 1.3×10⁻¹⁰) were pre-existing susceptibility risk factors (Figure S1 and Table S3). Of these NHL-W risk factors, dementia was nominally significant and had a similar effect size in HL (OR 3.7 [1.8–7.0], p = 8.3×10⁻⁵). This suggests dementia was a shared risk factor in NHL-W and HL for testing COVID-19 positive. We did not identify an age- or sex-specific interaction for these significant phecodes in NHL-W.

We also evaluated if any of the NHL-W risk factor effects were significantly different than the HL risk factor effects by modeling the interaction term of ethnicity (HL versus NHL-W) and the phecode (Methods). The COVID-19 susceptibility odds ratio increased by 1.5 [95% CI 1.1–2.0] (p = 0.004) if individuals were NHL-W and exhibited pre-existing fever of unknown origin compared with individuals who were HL and had pre-existing fever of unknown origin.

To determine if the risk factors were not correlated with and not already explained by previously identified COVID-19 risk factors as above (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease [Goyal et al., 2020; Grasselli et al., 2020a; Guan et al., 2020; Li et al., 2020; Yang et al., 2020a; Zhou et al., 2020a; Zhu et al., 2020] (Table S1 and Methods), we controlled for these in our model in addition to age and sex. For NHL-W, all pre-existing susceptibility risk factors including fever of unknown origin (OR 2.0 [1.6–2.4], p =

### Table 2. Risk of COVID-19 disease outcome in individuals self-identifying as Hispanic/Latinx versus Non-Hispanic/Latinx white with and without correction of known risk factors, related to Table S2

| Outcome (N Hispanic/Latinx; N Non-Hispanic/Latinx white) | Model covariates | Odds ratio [95% CI] | p value |
|---------------------------------------------------------|------------------|---------------------|---------|
| COVID-19 positive (562; 679) versus COVID-19 negative (8,725; 28,885) | Age, sex | 2.6 [2.3, 3.0] | <2.2×10⁻²² |
| | Age, sex, known risk factors | 2.5 [2.2, 2.8] | <2.2×10⁻²² |
| COVID-19 positive inpatient (132; 125) versus outpatient (430; 554) | Age, sex | 2.8 [2.0, 4.0] | 5.8×10⁻¹⁰ |
| | Age, sex, known risk factors | 2.5 [1.8, 3.6] | 1.4×10⁻⁷ |

CI, confidence interval.
1.7 × 10⁻¹³) remained significant after controlling for these known risk factors (Table S4). This result showed that fever of unknown origin, which could occur in cancer, occult infections, and inflammatory conditions (Roth and Basello, 2003), was a risk factor for COVID-19 positive testing in NHL-W independent of previously identified risk factors, and not observed as a risk factor in HL.

Pre-existing conditions in HL that are risk factors for COVID-19 hospitalization

Of the known COVID-19 risk factors, chronic kidney disease (OR 4.9 [2.7, 8.9], p = 2.1 × 10⁻⁷), hypertension (OR 3.2 [2.0, 5.1], p = 3.0 × 10⁻⁶), congestive heart failure (OR 5.5 [2.2, 15], p = 2.5 × 10⁻⁴), diabetes (2.1 [1.2, 3.5], p = 0.007), and coronary heart disease (OR 2.5 [1.2, 4.9], p = 0.01) were significant risk factors for hospitalization in HL. Chronic kidney disease (OR 2.7 [1.4, 5.1], p = 0.003), congestive heart failure (OR 2.8 [1.4,
5.8], p = 0.004), and coronary heart disease (OR 1.9 [1.1, 3.5], p = 0.03) were also significant risk factors for hospitalization in NHL-W.

When evaluating additional phecodes that may be pre-existing risk factors for hospitalization in HL, we found nonrheumatic mitral valve disorder (OR 18 [5.5–77], p = 1.1 × 10⁻¹⁴), hypertension (OR 3.2 [2.0–5.1], p = 3.0 × 10⁻¹⁰), sepsis (OR 5.3 [2.6–11], p = 4.5 × 10⁻⁶), respiratory failure (OR 14 [4.9–47], p = 1.3 × 10⁻⁷), and phecodes consistent with severe renal disorders including chronic renal failure (OR 6.5 [3.5–13], p = 7.5 × 10⁻⁶), acute renal failure (OR 7.1 [3.8–14], p = 1.4 × 10⁻⁶), end-stage renal disease (OR 7.1 [3.4–15], p = 2.0 × 10⁻⁷), renal dialysis (OR 7.7 [3.6–17], p = 2.0 × 10⁻⁷), and kidney transplant (OR 8.3 [3.5–20], p = 1.5 × 10⁻⁶) to be significant inpatient risk factors after multiple testing correction (Figure 3 and Table S5). Sepsis and acute renal failure were also significant NHL-W inpatient risk factors (sepsis OR 10 [4.5–25], p = 1.2 × 10⁻⁶; acute renal failure OR 5.8 [2.7–13], p = 6.4 × 10⁻⁶) (Figure 3 and Table S5). Respiratory failure and the other renal disorders were nominally significant NHL-W inpatient risk factors and similar in effect size to HL (Figure 3 and Table S5).

For these significant inpatient admission risk phecodes in HL and NHL-W, we found that only kidney transplant had a significant age >65 years interaction in HL for inpatient admission. Although age >65 years (OR 11 [6.5–19], p = 2.2 × 10⁻²²) and kidney transplant (OR 9.4 [4.1–23], p < 2.4 × 10⁻⁷) individually increased the inpatient admission risk, being both >65 years old and a kidney transplant recipient decreased this risk (OR 0.02 [1.4 × 10⁻⁴–0.50], p = 0.02). We did not identify a sex-specific interaction for these significant phecodes in HL and NHL-W.

**Nonrheumatic mitral valve disorder is a specific HL COVID-19 inpatient risk factor**

The risk factor effects of nonrheumatic mitral valve disorder and hypertension for HL was significantly increased compared with their risk factor effects in NHL-W. The inpatient odds ratio increased by 25 [95% CI 5–140] (p = 3.5 × 10⁻⁶) if individuals were HL and had nonrheumatic mitral valve disorder compared...
with individuals who were NHL-W and had nonrheumatic mitral valve disorder. The inpatient odds ratio increased by 2.3 [1.2–4.3] (p = 0.01) if individuals were HL and had hypertension compared with individuals who were NHL-W and had hypertension (Methods). Controlling for known risk factors in the HL group, nonrheumatic mitral valve disorders (OR 8.9 [3.8–22], p = 0.001) and respiratory failure (OR 6.5 [2.1–23], p = 0.001) remained significantly associated with inpatient admission suggesting they were not correlated with or already explained by previously identified COVID-19 risk factors (Table S6).

We determined if these COVID-19 inpatient risk factors observed in HL, but not in NHL-W, were also observed in another viral infection, influenza. Similar to COVID-19, HL ethnicity increased the risk of inpatient admission for individuals with influenza (OR 2.8 [2.1–4.0], p = 2.2 x 10^{-11}) and remained significantly elevated when correcting for known risk factors (OR 2.4 [1.7–3.4], p = 3.9 x 10^{-7}). In contrast to the observations in COVID-19 positive inpatients, nonrheumatic mitral valve disorder was not a pre-existing risk factor for hospitalization due to influenza for either HL or NHL-W individuals (Figure S2 and Table S7).

As with COVID-19, hypertension was a significant pre-existing risk factor for hospitalization due to influenza in HL individuals (OR 4.3 [2.4–7.8], p = 1.4 x 10^{-6}), but not in NHL-W individuals (Figure S2 and Table S7). Pre-existing renal disorders also conferred a similar risk of hospitalization for COVID-19 as they did for influenza in HL and NHL-W. Severe renal disorders including end-stage renal disease (OR 19 [8.2–47], p = 1.4 x 10^{-11}) and renal dialysis (OR 24 [9.1, 72], p = 1.3 x 10^{-15}) remained risk factors for hospitalization due to influenza only for HL individuals. Acute renal failure was a risk factor for hospitalization due to influenza for HL (OR 15 [7.8–28], p = 7.8 x 10^{-16}) and NHL-W (OR 8.5 [4.6–15], p = 5.8 x 10^{-11}) (Figure S2 and Table S7).

**Pre-existing conditions in HL that are risk factors for COVID-19 inpatient severe outcomes**

Of the known COVID-19 risk factors, hyperlipidemia was protective in HL for the COVID-19 positive inpatient severe outcome (OR 0.26 [0.08–0.71], p = 0.008) (Figure 2). This finding was not observed in NHL-W. We did not identify any additional phenocodes significantly associated with the COVID-19 Severe group, although our power was low (N = 35 HL, N = 19 NHL-W COVID-19 positive with severe outcome) compared to the COVID-19 Inpatient group (N = 132 HL, N = 125 NHL-W).

**Admission vitals and labs among COVID-19 positive inpatients**

One potential explanation for worse COVID-19 outcomes in HL could be that HL individuals presented to the health system with more severe disease. We therefore sought to determine if HL COVID-19 positive inpatient disease severity was reflected in more abnormal vital signs or laboratory values compared with NHL-W individuals. Controlling for age, sex, and known risk factors (Table S1), we analyzed vitals and labs +/- 1 day of inpatient admission date. White blood cell count (mean 7.93 ± standard deviation 4.2 x 10^3/µL HL versus 6.85 ± 4.0 x 10^3/µL NHL-W, p = 0.046), platelet count (216 ± 91 x 10^3/µL HL versus 187 ± 93 x 10^3/µL NHL-W, p = 0.023), creatinine (1.8 ± 2.7 mg/dL HL versus 1.3 ± 0.9 mg/dL NHL-W, p = 0.045), and C-reactive protein (9.0 ± 6.4 mg/dL HL versus 7.6 ± 6.5 mg/dL NHL-W, p = 0.011) were higher in HL COVID-19 positive inpatients compared with NHL-W COVID-19 positive inpatients (Table S3). This suggests hospitalized HL presented with a greater inflammatory response consistent with more advanced disease compared with hospitalized NHL-W.

**Extremes of COVID-19 outcome susceptibility or resistance**

Next, we identified HL individuals who were outliers based on what would be an expected COVID-19 clinical course predicated on their major predictive factors, namely, age and pre-existing conditions. These outlier groups included (1) individuals who were young with no major comorbidities (18–35 years old), but who were hospitalized, and (2) older individuals with high risk for a serious COVID-19 clinical course (>70 years old with at least three of the known risk factors), but who were not hospitalized. These individuals may represent extremes of COVID-19 susceptibility and resistance and therefore may carry genetic immunological susceptibilities or resistances to infection (Blanco-Melo et al., 2020; COVID-19 Host Genetics Initiative, 2020; Ellinghaus et al., 2020; Nguyen et al., 2020). Of the 105 young individuals with no major comorbidities, 8 (8%) were admitted to the hospital. These admitted individuals had either few pre-existing conditions (e.g., viral infection) or developmental delay. Of the 30 COVID-19 positive older individuals with a high risk for hospitalization, 9 (30%) were not hospitalized. These proportions were similar in NHL-W (5 inpatients of 138 young individuals with no major comorbidities [4%]; 40 not hospitalized of 88 COVID-19 positive older individuals with a high risk for hospitalization [45%]).
Pre-existing medications associated with COVID-19 outcomes

Controversy remains over the protective or detrimental effects of medication classes including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) (Mancia et al., 2020; Reynolds et al., 2020; Zhang et al., 2020c), immunosuppressants (D’Antiga, 2020; Mehta et al., 2020; Monti et al., 2020; Novi et al., 2020; Ritchie and Singanayagam, 2020), steroids (Shang et al., 2020; Zha et al., 2020), anticoagulants (Tang et al., 2020; Thachil, 2020; Thachil et al., 2020), and non-steroidal anti-inflammatory drugs (Little, 2020). We investigated whether the prescription of these medications 90 days before SARS-CoV-2 testing (see Table S8 for drugs assigned to each medication class) was associated with COVID-19 susceptibility, inpatient admission, or severe outcome while controlling for age, sex, and known risk factors (Methods). Comparing COVID-19 positive inpatients to outpatients, both HL and NHL-W individuals prescribed oral steroids (HL OR 3.5 [1.6, 7.8], p = 0.002; NHL-W OR 3.9 [1.9, 8.0], p < 0.001) or other immunosuppressants (HL OR 5.4 [2.3, 13.3], p < 0.001; NHL-W OR 4.6 [1.5, 13], p = 0.006) had increased risk of inpatient admission. We did not observe that being prescribed ACEI or ARBs increased the risk of testing positive for SARS-CoV-2, being admitted to the hospital, or having a severe course, as previously reported (Reynolds et al., 2020) (Tables 4 and S9).

Previous studies have not investigated the association of medication duration with COVID-19 outcomes as has been performed in influenza, where longer ACEI and ARB usage was protective for influenza incidence (Chung et al., 2020). In our study, comparing COVID-19 positive inpatients to outpatients, both HL and NHL-W individuals prescribed oral steroids (HL OR 3.5 [1.6, 7.8], p = 0.002; NHL-W OR 3.9 [1.9, 8.0], p < 0.001) or other immunosuppressants (HL OR 5.4 [2.3, 13.3], p < 0.001; NHL-W OR 4.6 [1.5, 13], p = 0.006) had increased risk of inpatient admission. We did not observe that being prescribed ACEI or ARBs increased the risk of testing positive for SARS-CoV-2, being admitted to the hospital, or having a severe course, as previously reported (Reynolds et al., 2020) (Tables 4 and S9).

**DISCUSSION**

Identifying COVID-19 risk factors can inform patient care, public policies, and future research aimed at improving outcomes and reducing health care disparities. We leveraged our ability to query de-identified electronic health records to determine COVID-19 risk factors for HL in the UCLA Health System. Our analysis at the individual patient-level successfully captured the results of previously reported risk factors for more severe COVID-19 disease, such as chronic renal disease, diabetes, and hypertension across ethnicities (Goyal et al., 2020; Grasselli et al., 2020a, 2020b; Guan et al., 2020; Gupta et al., 2020; Li et al., 2020; Yang et al., 2020a; Zhou et al., 2020a; Zhu et al., 2020), validating our EHR-based approach. Our analysis
at the individual, patient level also successfully captured the results of previously reported health disparities in HL individuals who were identified at the aggregate level (Chicago Department of Public Health, 2020; Los Angeles County Department of Public Health, Chief Science Office, 2020; New York City Health, 2020; Rodriguez-Diaz et al., 2020). Moreover, we identified risk factors for COVID-19 inpatient admission, some of which were specific to HL and not observed as risk factors in NHL-W.

Having pre-existing nonrheumatic mitral valve disorder was an HL risk factor for hospitalization, but this condition was not observed as a risk factor in NHL-W. Nonrheumatic mitral valve disorder has not been previously reported to be a COVID-19 risk factor, possibly because it has not been evaluated in the HL population. Nonrheumatic mitral valve disorder was not correlated with known risk factors such as coronary heart disease and was specific to COVID-19, as it was not an influenza inpatient risk factor in HL individuals. Previous studies investigating influenza inpatient admission risk factors did not identify mitral valve disorders either (Ono et al., 2016; Puig-Barberà et al., 2016). It is possible that symptoms of mitral valve disorders such as underlying dyspnea may exacerbate COVID-19 symptoms leading to an increased risk of inpatient admission. Further studies are necessary to validate this risk factor and determine the mechanism of association.

Significant risk factors for becoming critically ill (intensive care unit admission or death) among hospitalized COVID-19 patients include hypertension, renal disease (chronic renal disease, acute kidney injury), cardiac disease (cardiac injury, coronary artery disease), pulmonary disease (chronic obstructive pulmonary disease, acute respiratory distress syndrome), diabetes, hyperlipidemia, and obesity (Arzegniano et al., 2020; Hirsch et al., 2020; Huang et al., 2020; Li et al., 2020; Lighter et al., 2020; Wang et al., 2020; Williamson et al., 2020; Zhou et al., 2020a). These analyses were performed in China, Italy, United Kingdom and United States, and not sub-grouped by ethnicity if applicable. Many of these risk factors including chronic kidney disease, hypertension, congestive heart failure, diabetes, and coronary heart disease were HL risk factors for inpatient admission. Additional renal disorders such as acute renal failure, end-stage renal

### Table 4. Pre-existing medications associated with COVID-19 disease outcomes, related to Figure S3, Tables S8, and S9

#### Hispanic/Latinx

| Medication        | COVID-19 Positive (N = 562) versus negative (N = 8,725) | Inpatient (N = 132) versus Outpatient (N = 430) | Severe (N = 35) versus Not Severe (N = 97) |
|-------------------|--------------------------------------------------------|-------------------------------------------------|------------------------------------------|
|                   | OR [95% CI] Npos Nneg                                  | OR [95% CI] NInp NOut                          | OR [95% CI] NSev Nnot Sev               |
| ACE Inh           | 1.4 [0.9, 2.1] 24 302                                  | 0.8 [0.3, 2.3] 9 15                            | 1.8 [0.3, 8.5] 2 7                     |
| ARBs              | 0.9 [0.5, 1.5] 17 317                                  | 0.8 [0.3, 2.6] 9 8                            | 1.5 [0.3, 7.6] 2 7                     |
| Immuno suppressants | 1.1 [0.8, 1.6] 38 493                           | 5.4 [2.3, 13]* 23 15                          | 1.0 [0.3, 3.4] 6 17                    |
| Steroids          | 0.9 [0.7, 1.3] 44 712                                  | 3.5 [1.6, 7.8]* 23 21                         | 0.4 [0.1, 1.3] 3 20                    |
| Anticoagulant     | 1.0 [0.5, 2.0] 8 134                                  | 0.7 [0.1, 3.6] 5 3                            | 5.2 [0.7, 37] 2 3                     |
| NSAID             | 0.9 [0.6, 1.2] 42 749                                  | 0.6 [0.2, 1.3] 10 32                          | 0.5 [0.1, 2.5] 1 9                     |

#### Non-Hispanic/Latinx white

| Medication        | COVID-19 positive (N=679) versus negative (N=28,885) | Inpatient (N=125) versus Outpatient (N=554) | Severe (N=19) versus Not Severe (N=106) |
|-------------------|------------------------------------------------------|-------------------------------------------|----------------------------------------|
|                   | OR [95% CI] Npos Nneg                                  | OR [95% CI] NInp NOut                          | OR [95% CI] NSev Nnot Sev               |
| ACE Inh           | 1.1 [0.7, 1.6] 22 934                                  | 1.1 [0.4, 3.0] 8 14                            | 1.3 [0.12, 7.7] 1 7                     |
| ARBs              | 1.2 [0.8, 1.7] 30 1,237                                | 1.1 [0.4, 3.1] 10 20                           | 0.22 [0.2, 10] 0 10                     |
| Immunosuppressants | 1.0 [0.6, 1.6] 19 788                               | 4.6 [1.5, 13]* 10 9                           | 0.2 [0.1, 10] 0 10                      |
| Steroids          | 1.1 [0.8, 1.5] 49 1,940                                | 3.9 [1.9, 8.0]* 23 26                         | 0.4 [0.1, 1.5] 2 21                     |
| Anticoagulant     | 1.0 [0.5, 1.6] 14 595                                  | 5.8 [1.3, 36]* 12 2                           | 1.6 [0.3, 7.2] 2 10                     |
| NSAID             | 1.0 [0.8, 1.4] 52 2,259                                | 2.6 [1.3, 5.4]* 18 34                         | 0.6 [0.1, 2.2] 2 16                     |

CI, confidence interval; pos, positive; neg, negative; Inp, Inpatient; Out, outpatient; Sev, Severe; not Sev, Not Severe, ACE inh, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; NSAID = non-steroidal anti-inflammatory drug.

*p < 0.05.
disease, and renal dialysis were risk factors for hospitalization in HL individuals and were also risk factors in NHL-W individuals. Hypertension, on the other hand, was a much stronger risk factor for hospitalization in HL than in NHL-W. For COVID-19 severe outcomes in our study, hyperlipidemia decreased risk in HL. Previous studies have been mixed on cholesterol risk in COVID-19 as hyperlipidemia increased the risk for mortality among patients in the intensive care unit (Grasselli et al., 2020b), but lower cholesterol levels were associated with COVID-19 inpatient severity (Wei et al., 2020). Last, reduced vitamin D has been variably associated with worse COVID-19 outcomes, and a pilot clinical trial of vitamin D treatment showed improved outcomes (Entrenas Castillo et al., 2020; Ilie et al., 2020; Jain et al., 2020; Rhodes et al., 2020). However, we did not find an association of pre-existing vitamin D insufficiency with any COVID-19 outcomes.

The risk of inpatient admission for HL compared with NHL-W remained elevated even when controlling for multiple comorbidities. One contributing explanation could be that HL patients present initially with more advanced disease. To address this objectively, we compared whether presenting vital signs or laboratory values were more severe for HL inpatients than NHL-W inpatients. Although vital signs were similar in both groups, we found that HL had higher white blood cell counts, platelets, creatinine, and C-reactive protein, all potential inflammatory and acute phase reactants consistent with more advanced disease (Ayalew, 2020; Kushner, 2020). Previous studies have shown leukocytosis, elevated creatinine, and elevated C-reactive protein were associated with a severe COVID-19 outcome among hospitalized patients (Ali et al., 2020; Cheng et al., 2020; Li et al., 2020; Zhang et al., 2020a, 2020b; Zhou et al., 2020a). Thrombocytopenia, rather than thrombocytosis, during hospitalization was a risk factor for severe COVID-19 outcome (Goyal et al., 2020; Guan et al., 2020; Huang et al., 2020; Lippi et al., 2020; Yang et al., 2020b).

There has been concern that some individuals with COVID-19 have an exaggerated immune response resulting in cytokine storm or secondary hemophagocytic lymphohistiocytosis, and studies have suggested that short-term immunosuppression is warranted (Mehta et al., 2020; Ritchie and Singanayagam, 2020; Zhou et al., 2020b). Previous studies investigated small numbers of COVID-19 positive individuals (<4) on immunosuppression before COVID-19 diagnosis, finding that these individuals in general did well and did not have a severe outcome (D’Antiga, 2020; Monti et al., 2020; Novi et al., 2020). Here we analyzed 150 individuals on either oral steroids or other immunosuppressants. Both HL and NHL-W individuals on oral steroids or immunosuppressants had an increased risk of inpatient admission. These medications did not increase the risk of an inpatient severe outcome, although the Severe analysis group had less power. The explanation for increased risk of inpatient admission may be biological or due to clinician bias. Immunosuppressed COVID-19 individuals may have more severe symptoms requiring inpatient admission. Clinicians may also have a lower threshold of inpatient admission for patients on immunosuppressive medication. We did not assess whether immunosuppressive medication was stopped, continued, or changed on admission, and therefore, we are unable to draw conclusions on whether to adjust immunosuppression in COVID-19 hospitalized patients.

Recognizing COVID-19 risk factors can encourage individuals with these risk factors to take appropriate precautions, understand how pre-morbid conditions may affect COVID-19 disease, anticipate necessary medical treatment, and possibly reduce risk by managing these conditions (CDC, 2020). Public health measures to promote accurate COVID-19 information for the general population may not be as effective in minority populations. In Pennsylvania, the Center for Disease Control and Prevention’s (CDC) Racial and Ethnic Approaches to Community Health (REACH) program engaged HL community leaders and learned that the community had difficulty accessing reliable information in Spanish (Calo et al., 2020). As such REACH disseminated Spanish written resources for COVID-19 and hosted multiple Spanish-language community-facing COVID-19 information sessions. The Los Angeles County of Public Health recommended engaging communities to provide culturally and linguistically appropriate outreach, education, and engagement (Los Angeles County Department of Public Health, Chief Science Office, 2020). They established a COVID-19 website with information and educational materials in multiple languages including Spanish (Los Angeles County of Public Health, 2020). The Latino Coalition for a Healthy California also provided COVID-19 information and hosted webinars in Spanish (Latino Coalition for a Healthy California, 2020).

This study identifies risk factors for COVID-19 inpatient admission that are specific to HL and others that were shared with NHL-W. These risk factors should spur future work in understanding the mechanistic underpinnings of these observations and implementing equitable strategies to mitigate these risk factors.
Limitations of the study

Additional explanations for the increased HL inpatient admission risk compared with NHL-W may be environmental such as air pollution (Brandt et al., 2020), socioeconomic such as access to health care (Chowkwanyun and Reed, 2020; Ong et al., 2020), delay from symptom onset to health care presentation (Chowell et al., 2012), and genetic susceptibility (COVID-19 Host Genetics Initiative, 2020; Kuo et al., 2020). These additional covariates were not available in our de-identified EHR dataset. Geographical location like zip codes was not available to link environmental exposures such as air pollution (Wang et al., 2020a; Zoran et al., 2020) or temperatures (Poirier et al., 2020). We also did not have data regarding socioeconomic factors such as income or health insurance, which has been used as a proxy for socioeconomic status in other studies (Casey et al., 2018). We did not analyze data from the fall and winter seasons of 2020 as the study period was from March 9, 2020, to August 31, 2020. We did not investigate all self-identified minority race groups such as African Americans. The sample size of African Americans with COVID-19 was 70% less than Hispanics/Latinx with only 10 African Americans with a severe outcome. Focusing on other minority groups, longer study periods, environmental factors, and socioeconomic factors are areas of future work to be pursued.

Resource availability

Lead contact

Requests for additional information can be directed to the Lead Contacts: Timothy S Chang (timothychang@mednet.ucla.edu); Manish J Butte (mbutte@mednet.ucla.edu); Bogdan Pasaniuc (bpasaniuc@mednet.ucla.edu),

Material availability

This study did not generate unique reagents.

Data and code availability

Individual electronic health record data are not publicly available due to patient confidentiality and security concerns. Collaboration with the study authors who have been approved by UCLA Health for Institutional Review Board-qualified studies are possible and encouraged. Code is available on GitHub: https://github.com/TSChang-Lab/preexisiting-conditions-HL-COVID19.

METHODS

All methods can be found in the accompanying Transparent methods supplemental file.

CONSORTIA

UCLA Precision Health Data Discovery Repository Working Group

Anna L. Antonio, Maryam Ariannejad, Angela M. Badillo, Brunilda Balliu, Yael Berkovich, Michael Broudy, Tony Dang, Chris Denny, Eleazar Eskin, Eran Halperin, Brian L. Hill, Ankur Jain, Vivek Katakwar, Clara Lajonchere, Clara Magyar, Sheila Minton; Ghouse Mohammed, Ariff Muhamed, Pabba Pavan, Michael A. Pfeffer, Nadav Rakocz, Akos Rudas, Rey Salonga, Timothy J. Sanders, Paul Tung, Vu Vu, Ailsa Zheng.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102188.

ACKNOWLEDGMENTS

Funding/support: This work was supported by grants R25NS065723 from the Neurological Disorders and Stroke of the National Institutes of Health, the UCLA David Geffen School of Medicine - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program, and the UCLA David Geffen School of Medicine Oversight COVID-19 Research Committee.

AUTHOR CONTRIBUTIONS

Conceptualization, T.S.C, Y.D., M.K.F., R.J., T.S., J.M.Y., C.H., D.A.W., D.H.G., M.J.B., and B.P.; Methodology, T.S.C, Y.D., M.K.F., J.M.Y., C.H., M.J.B., and B.P.; Software, T.S.C, Y.D., M.K.F., R.J., and T.S.;
Validation, T.S.C., Y.D., M.K.F., R.J., and T.S.; Formal Analysis, T.S.C., Y.D., M.K.F., R.J., and T.S.; Investigation, T.S.C., Y.D., M.K.F., R.J., and T.S.; Resources, D.H.G., M.J.B., B.P., and UCLA Precision Health Data Discovery Repository Working Group; Data Curation, T.S.C., Y.D., M.K.F., R.J., and T.S.; and UCLA Precision Health Data Discovery Repository Working Group; Writing – Original Draft, T.S.C., M.K.F., D.H.G., B.P.; Writing – Review & Editing, T.S.C., Y.D., M.K.F., R.J., T.S., J.M.Y., C.H., D.H.G., M.J.B., and B.P.; Visualization, T.S.C., Y.D., and M.K.F.; Supervision, T.S.C., M.J.B., and B.P.; Funding Acquisition, D.H.G., M.J.B., and B.P.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 14, 2020
Revised: January 2, 2021
Accepted: February 9, 2021
Published: March 19, 2021

REFERENCES

Ali, H., Dasoud, A., Mohamed, M.M., Salim, S.A., Yessayan, L., Baharan, J., Murtaza, A., Rao, V., and Soliman, K.M. (2020). Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren. Fail. 42, 393–397.

Argenziano, M.G., Bruce, S.L., Slater, C.L., Tiao, J.R., Baldwin, M.R., Ban, R.G., Chang, B.P., Chau, K.H., Choo, J.J., Gavin, N., et al. (2020). Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 369, m1796.

Ayalew, T. (2020). Approach to the Patient with Thrombocytosis (UpToDate).

Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T.X., Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.-C., Thrombocytosis (UpToDate).

Brandt, E.B., Beck, A.F., and Mersha, T.B. (2020). Air pollution, racial disparities, and COVID-19 existing chronic disease prevention programs. Prev. Chronic Dis. 17, 200165.

Calo, W.A., Murray, A., Francis, E., Bermudez, M., and Kraschnewski, J. (2020). Reaching the hispanic community about COVID-19 through home/latest-data.html.

Chowell, G., Echevarria-Zuno, S., Vboud, C., Simonsen, L., Miller, M.A., Fernández-Garate, I., González-Bonilla, C., and Borja-Aburto, V.H. (2012). Epidemiological characteristics and underlying risk factors for mortality during the autumn 2009 pandemic wave in Mexico. PLoS One 7, e41069.

Chowkwanyun, M., and Reed, A.L. (2020). Racial health disparities and covid-19 - caution and context. N. Engl. J. Med. 383, 201–203.

Chung, S.-C., Providencia, R., and Sofat, R. (2020). Association between angiotensin blockade and incidence of influenza in the United Kingdom. N. Engl. J. Med. 383, 397–400.

COVID-19 Host Genetics Initiative (2020). The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718.

D’Antiga, L. (2020). Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 26, 832–834.

Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albulos, A., Invernizzi, P., Fernández, J., Prats, D., Baseli, G., Asselta, R., et al. (2020). Genomewide association study of severe covid-19 with respiratory failure. N. Engl. J. Med. 383, 1522–1534.

Engerer, S., Courteille, E., Chambon, P., Ringel, J.B., et al. (2020). Baseline characteristics of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574–1581.

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabirini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020a). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs in Lombardy, Italy. JAMA Intern. Med. 180, 1345–1355.

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Li, M., Shan, H., Lei, C., Hui, D.S.C., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720.

Gupta, S., Hayek, S.S., Wang, W., Chan, L., Mathews, K.S., Melamed, M.L., Brenner, S.K., Leonberg-Yoo, A., Schenck, E.J., Radbel, J., et al. (2020). Factors associated with death in critically
ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 183, 1–12.

Hirsch, J.S., Ng, J.H., Ross, D.W., Sharma, P., Shah, H.H., Barnett, R.L., Hazzan, A.D., Fishbane, S., Beaven, K.D. Northwell COVID-19 Research Consortium, et al. (2020). Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 97, 827–838.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Ilie, P.C., Stefanescu, S., and Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin. Exp. Res. 32, 1195–1198.

Jain, A., Chaussaria, R., Sengar, N.S., Singh, M., Mahor, S., and Narain, S. (2020). Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci. Rep. 10, 20191.

Kuo, C.-L., Pilling, L.C., Atkins, J.L., Masoli, J.A.H., Johnson, D., Francois, F., and Stachel, A. (2020). The role of non-steroidal anti-inflammatory drugs and covid-19. BMJ 376, 1185.

Kushner, I. (2020). Acute Phase Reactants (UpToDate).

Los Angeles County Department of Public Health Chief Science Office (2020). COVID-19 Racial, Ethnic & Socioeconomic Data & Strategies Report, http://publichealth.lacounty.gov/docs/RacialEthnicSocioeconomicDataCOVID19.pdf.

Los Angeles County Department of Public Health (2020). COVID-19 Media Page (LA County Department of Public Health).

Mancia, G., Rea, F., Ludergnani, M., Apolone, G., and Corrao, G. (2020). Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N. Engl. J. Med. 382, 2441–2448.

Martinez, D.A., Hinson, J.S., Klein, E.Y., Irvin, N.A., Saheerd, M., Page, K.R., and Levin, S.R. (2020). SARS-CoV-2 positivity rate for latinos in the baltimore-Washington, DC region. JAMA 324, 392–395.

Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., and Manson, J.J. J. HU Across Specialty Collaboration, UK (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034.

Monti, S., Balduzzi, S., Delvino, P., Bellis, E., Quadrelli, V.S., and Montecucco, C. (2020). Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 79, 667–668.

New York City Health (2020). Age-adjusted rates of lab confirmed COVID-19, https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-04162020-1.pdf.

Nguyen, A., David, J.K., Maden, S.K., Wood, M.A., Weeder, B.R., Nellore, A., and Thompson, R.F. (2020). Human leukocyte antigen susceptibility map for SARS-CoV-2. J. Virol. 94, e00510–20.

Novi, G., Mikulska, M., Briano, F., Toscanini, F., Tazza, F., Uccelli, A., and Inglese, M. (2020). COVID-19 in a 34-year-old patient treated with tocilizumab: does immunosuppression have a protective role? Mult. Scler. Relat. Disord. 42, 102120.

Ono, S., Ono, Y., Matsui, H., and Yasunaga, H. (2016). Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort: BMC Public Health 16, 922.

Poirier, C., Luo, W., Majumder, M.S., Liu, D., Mandi, K.D., Mooreing, T.A., and Santillana, M. (2020). The role of environmental factors on transmission rates of the COVID-19 outbreak: an initial assessment in two spatial scales. Sci. Rep. 10, 17002.

Puig-Barberà, J., Natividad-Sancho, A., Trushakova, S., Sominina, A., Pisareva, M., Ciblak, M.A., Badur, S.Y., Hu, H., Coller, S.J., El Guerech-Sciblan, C., et al. (2016). Epidemiology of hospital admissions with influenza during the 2013/2014 northern hemisphere influenza season: results from the global influenza hospital surveillance network. PLoS One 11, e0154970.

Reynolds, H.R., Adhikari, S., Pulgarin, C., Troxel, A.B., Irritate, E., Johnson, S.B., Hausvater, A., Newman, J.D., Berger, J.S., Bangalore, S., et al. (2020). Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N. Engl. J. Med. 382, 2441–2448.

Rhodes, J.M., Subramanian, S., Laird, E., and Kenny, R.A. (2020). Editorial: low population density is an epidemiological feature of COVID-19 infection: an initial assessment in two spatial scales. Science 368, 1434–1437.

Ritchie, A.I., and Singanayagam, A. (2020). Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet 395, 1111.

Rodriguez-Díaz, C.E., Guilamo-Ramos, V., Mena, L., Hall, E., Honermann, B., Crowley, J.S., Baral, S., Prado, G.J., Marzan-Rodriguez, M., Beyrer, C., et al. (2020). Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics. Ann. Epidemiol 52, 46–53.e2.

Roth, A.R., and Basello, G.M. (2003). Approach to the adult patient with fever of unknown origin. Am. Fam. Physician 68, 2223–2228.

Shang, L., Zhao, J., Hu, Y., Du, R., and Cao, B. (2020). On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395, 683–684.

Tang, N., Bai, H., Chen, X., Gong, J., Li, D., and Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 18, 1094–1099.

Thachil, J. (2020). The versatile heparin in COVID-19. J. Thromb. Haemost. 18, 1020–1022.

Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levy, M., Clark, C., and Iba, T. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. 18, 1023–1026.

The Lancet. (2020). Sustaining containment of COVID-19 in China. Lancet 395, 1230.

US Bureau of Labor Statistics (2019). Labor force characteristics by race and ethnicity 2018, https://www.bls.gov/opub/reports/race-and-ethnicity/2018/pdf/home.pdf.

US Department of Health and Human Services (2018). 2017 National Healthcare Quality and Disparities Report (AHRQ Publication).

Velasco-Mondragon, E., Jimenez, A., Palladino-Davis, A.G., Davis, D., and Escamilla- Cejudo, J.A. (2016). Hispanic health in the USA: a scoping review of the literature. Public Health Rev. 37, 31.

Wang, B., Liu, J., Li, Y., Fu, S., Xu, X., Li, L., Zhou, J., Liu, X., He, X., Yan, J., et al. (2020a). Airborne particulate matter, population mobility and COVID-19: a multi-city study in China. BMC Public Health 20, 1585.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020b). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. JAMA 323, 1061–1069.

Wei, W.-Q., Bastarache, L.A., Carroll, R.J., Marlo, J.E., Osterman, T.J., Gamazon, E.R., Cox, N.J., Roden, D.M., and Denny, J.C. (2017). Evaluating pharmaceutical, clinical classification software, and iCD-9-CM codes for phenotype-wide association studies in the electronic health record. PLoS One 12, e0175508.

Wei, X., Zeng, W., Su, J., Wan, H., Yu, X., Cao, X., Tan, W., and Wang, H. (2020). Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 14, 297–304.
Weng, C.-H., Saal, A., Butt, W.W.W., and Chan, P.A. (2020). Characteristics and clinical outcomes of COVID-19 in Hispanic/Latino patients in a community setting: a retrospective cohort study. J. Med. Virol. 93, 115–117.

Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436.

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., and Zhou, Y. (2020a). Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95.

Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., and Shang, Y. (2020b). Thrombocytopenia and its association with mortality in patients with COVID-19. J. Thromb. Haemost. 18, 1469–1472.

Zha, L., Li, S., Pan, L., Tefsen, B., Li, Y., French, N., Chen, L., Yang, G., and Villanueva, E.V. (2020).

Zhang, J.-J., Cao, Y.-Y., Tan, G., Dong, X., Wang, B.-C., Lin, J., Yan, Y.-Q., Liu, G.-H., Akdis, M., Akdis, C.A., et al. (2020a). Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 76, 533–550.

Zhang, J.J.Y., Lee, K.S., Ang, L.W., Leo, Y.S., and Young, B.E. (2020b). Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin. Infect. Dis. 71, 2199–2206.

Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020c). Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671–1681

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020a). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054–1062.

Zhou, Z.G., Xie, S.M., Zhang, J., Zheng, F., Jiang, D.X., Li, K.Y., Zuo, Q., Yan, Y.S., Liu, J.Y., Xie, Y.L., et al. (2020b). Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy. Preprints, 2020030065.

Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., et al. (2020). Association of blood glucose Control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31, 1068–1077.e3.

Zoran, M.A., Savastru, R.S., Savastru, D.M., and Tautan, M.N. (2020). Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy. Sci. Total Environ. 738, 139625.
Supplemental information

Pre-existing conditions
in Hispanics/Latinxs
that are COVID-19 risk factors

Timothy S. Chang, Yi Ding, Malika K. Freund, Ruth Johnson, Tommer Schwarz, Julie M. Yabu, Chad Hazlett, Jeffrey N. Chiang, David A. Wulf, UCLA Precision Health Data Discovery Repository Working Group, Daniel H. Geschwind, Manish J. Butte, and Bogdan Pasaniuc
Figure S1. Related to Figure 3. Significant pre-existing condition risk factors for COVID-19 susceptibility correcting for age and sex (Model 1) grouped by phecode category for Hispanics/Latinxs (blue) and Non-Hispanic/Latinx whites (purple). 95% confidence intervals for odds ratios are shown. Solid lines indicate risk factors that are Bonferroni significant. Dotted lines are not Bonferroni significant. neo = neoplasm, Bonf = Bonferroni.
Figure S2. Related to Figure 3. For phecodes that were significant COVID-19 risk factors for hospitalization in Hispanics/Latinxs or Non-Hispanics/Latinx whites, the phecode odds ratios and 95% confidence intervals of influenza inpatient admission correcting for age and sex (Model 1) are shown for Hispanics/Latinxs (blue) and Non-Hispanics/Latinx whites (purple). Solid lines indicate risk factors that are Bonferroni significant. Dotted lines are not Bonferroni significant. inf = infectious, heme = hematopoietic, Bonf = Bonferroni.
Figure S3. Related to Table 4. COVID-19 inpatient admission odds ratio for medication prescription 90 days prior to SARS-CoV-2 testing (Any), medication prescription duration for less than one year (< 1 Yr), and medication prescription duration greater than one year (≥ 1 Yr) for Hispanics/Latinx and Non-Hispanic/Latinx whites. ACEI = angiotensin converting enzyme inhibitors, AntiCoag = anticoagulant, ARB = angiotensin receptor blockers, Immunosup = immunosuppressant, NSAID = non-steroidal anti-inflammatory drugs.
Table S2. Related to Table 2. Risk of COVID-19 disease outcome in individuals self-identifying as Hispanic/Latinx versus Non-Hispanic/Latinx white with and without correction of known risk factors. Includes age and sex covariate effects. CI = confidence interval, HL = Hispanics/Latinxs, OR = odds ratio

| Outcome (N_{Hispanic/Latinx}; N_{Non-Hispanic/Latinx white}) | Model Covariates | HL OR [95% CI], p-value | Age OR [95% CI], p-val | Age² OR (per 1000 years²) [95% CI], p-val | Sex OR (Female) [95% CI], p-val |
|---------------------------------------------------------------|-------------------|--------------------------|-------------------------|------------------------------------------|-------------------------------|
| COVID-19 positive (562; 679) vs COVID-19 negative (8,725; 28,885) | age, sex          | 2.6 [2.3, 3.0] <2.2 x 10⁻²² | 1.0 [0.99-1.01], 0.89  | 0.94 [0.83-1.06], 0.30                  | 0.85 [0.76-0.95], 5.4x10⁻³   |
|                                                              | age, sex, known risk factors | 2.5 [2.2, 2.8] <2.2 x 10⁻²² | 1.0 [0.99-1.01], 0.71  | 0.94 [0.83-1.07], 0.35                  | 0.84 [0.75-0.95], 3.7x10⁻³   |
| COVID-19 positive Inpatient (132; 125) vs Outpatient (430; 554) | age, sex          | 2.8 [2.0, 4.0] 5.8 x 10⁻¹⁰ | 0.96 [0.93-0.99], 0.03 | 2.4 [1.7-3.4], 2.1x10⁻⁷             | 0.65 [0.48-0.89], 6.4x10⁻³   |
|                                                              | age, sex, known risk factors | 2.5 [1.8, 3.6] 1.4 x 10⁻⁷ | 0.97 [0.94-1.01], 0.14 | 2.0 [1.4-2.7], 1.7x10⁻⁴             | 0.71 [0.52-0.98], 0.04       |

Transparent Methods

Study design
This was an observational case-control study within a cohort of patients registered at the UCLA Health System after January 1, 2013. The UCLA Health System includes two hospitals (520 and 281 inpatient beds) and 210 primary and specialty outpatient locations predominantly within Los Angeles County. We leveraged an extract of the de-identified EHR from the UCLA Health System known as the UCLA Data Discovery Repository (DDR), developed under the auspices of the UCLA Health Office of Health Informatics Analytics and the UCLA Institute of Precision Health. The DDR contains longitudinal electronic records for more than 1.5 million patients since 2013, including patient demographics, problems, medications, vital signs, past medical history, and laboratory data. UCLA Health serves roughly five percent of Los Angeles county, which is the main catchment area. Individuals in Los Angeles county are seen by other public and private hospitals, some of which service a higher percentage of Hispanic/Latinx (HL) individuals and some of which service a higher percentage of Non-Hispanic/Latinx white (NHL-W) individuals (UC Health, 2019; UCLA Health, 2020; U.S. Census Bureau, 2018). This study was considered human subjects research exempt by the UCLA Institutional Review Board because all electronic health records were de-identified (UCLA IRB# 20-001180).

Inclusion/Exclusion Criteria for Case/Control Selection
From March 9, 2020 to August 31, 2020, 82,681 individuals were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via reverse transcriptase polymerase chain reaction (RT-PCR) within the UCLA Health System. The first positive SARS-CoV-2 PCR test was reported on March 12, 2020. Three different levels of COVID-19 outcome were defined (Figure 1).

COVID-19 positive cases were those with a positive SARS-CoV-2 PCR test result (COVID-19 positive). To determine individuals with SARS-CoV-2 testing, lab tests in the DDR were searched for “SARS-CoV-2” or “COVID-19”. The list of tests was manually reviewed to determine which tests were PCR based. SARS-CoV-2 PCR tests in our hospital system reported positive tests as “positive” or “detected” and negative tests as “negative” or “not detected”. Other values such as “unknown” or “NULL” were considered unknown. Some individuals had more than one SARS-CoV-2 PCR test; in these cases, individuals were considered COVID-19 positive if they had at least one positive test. The controls for COVID-19 positive cases were COVID-19 negative individuals who were tested for SARS-CoV-2 but had negative results.

Inpatient cases were those who had a hospital admission within 14 days of their first positive SARS-CoV-2 PCR test (Inpatients). This time window was selected to identify individuals whose symptoms may not have been severe at initial testing, but may have progressed in severity warranting inpatient admission. The controls for inpatient cases were those who tested positive for COVID-19, but were not admitted as an inpatient within 14 days of their first positive SARS-CoV-2 PCR test (Outpatients).

Severe cases were those who were admitted to an intensive care unit or were intubated within 14 days of their first positive SARS-CoV-2 PCR test (Severe). Intubation was determined from a custom field based on the vital flowsheet, “AirwayMinutes”, which is the time in minutes a patient was intubated. The controls for Severe cases were those who had a hospital admission within 14 days of their first positive SARS-CoV-2 PCR test, but were not admitted to an intensive care unit and not intubated during the 14-day window (Inpatient Not Severe).
To determine pre-existing conditions and medications associated with COVID-19 outcome in HL and NHL-W, we performed separate analyses for the HL group and the NHL-W group. The HL group included individuals self-identifying as HL and any race. The NHL-W group included subjects self-identifying as Non-HL for ethnicity and white for race. We did not include all Non-HL races as this group included minorities such individuals who self-identified as Non-HL, Black or African American.

Individuals were excluded if all SARS-CoV-2 test results were unknown, their records were missing age, their records were missing sex, or there was no encounter in the UCLA Health System prior to the SARS-CoV-2 PCR test.

**Confounding variables**

We treated sex, age, and age^2 as potential confounders. Pre-existing known COVID-19 risk factors (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease (Goyal et al., 2020; Grasselli et al., 2020a, 2020b; Guan et al., 2020; Gupta et al., 2020; Li et al., 2020; Yang et al., 2020; Zhou et al., 2020; Zhu et al., 2020)) were also considered potential confounders for specific analyses as described below (see Table S1 for phecodes assigned to risk factors).

**Statistical Analysis**

**Demographics**

Age, sex, race and ethnicity were stratified by the Tested, COVID-19 positive, Inpatient and Severe groups. For age groups and sex, percentages of Severe was compared to Inpatient, Inpatient was compared to COVID-19 positive, and COVID-19 positive was compared to Tested using a Fisher's exact test (Fisher, 1922). Age groups were: <18 years, 19-35 years, 36-50 years, 51-65 years, and >65 years. Significant association of race and ethnicity in a COVID-19 outcome was analyzed in the following Firth logistic regression models (McCullagh and Nelder, 1989).

\[
\logit(\text{outcome}) = \beta_0 + \beta_1 \text{race} + \beta_2 \text{age}_\text{group} + \beta_3 \text{sex}
\]

and

\[
\logit(\text{outcome}) = \beta_0 + \beta_1 \text{ethnicity} + \beta_2 \text{age}_\text{group} + \beta_3 \text{sex}
\]

Outcome for Severe was considered Inpatient Severe vs. Inpatient Not Severe; for Inpatient was considered COVID-19 positive Inpatient vs COVID-19 positive Outpatient; and for COVID-19 positive was considered COVID-19 positive vs. COVID-19 negative.

We also compared HL to NHL-W controlling for age and sex using the Firth logistic regression model:

\[
\logit(\text{outcome}) = \beta_0 + \beta_1 \text{Hispanic/Latinx} + \beta_2 \text{age} + \beta_3 \text{age}_\text{group}^2 + \beta_4 \text{sex}
\]

We corrected for pre-existing known risk factors (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease (Goyal et al., 2020; Grasselli et al., 2020a, 2020b; Guan et al., 2020; Gupta et al., 2020; Li et al., 2020; Yang et al., 2020; Zhou et al., 2020; Zhu et al., 2020)) using the Firth logistic regression model:

\[
\logit(\text{outcome}) = \beta_0 + \beta_1 \text{Hispanic/Latinx} + \beta_2 \text{age} + \beta_3 \text{age}_\text{group}^2 + \beta_4 \text{sex} + \beta_5 \text{coronary_artery_disease} + \beta_6 \text{congestive_heart_failure} + \beta_7 \text{chronic_obstructive_pulmonary_disease} + \beta_8 \text{type_2_diabetes} + \beta_9 \text{hyperlipidemia} + \beta_10 \text{hypertension} + \beta_11 \text{obesity} + \beta_12 \text{chronic_renal_disease}
\]

See Table S1 for phecodes assigned to these known risk factors. Age and age squared were included in the model to correct for residual confounding effects of age due to possible non-linear effect. We used the likelihood ratio test to test for significance of HL ethnicity.

**Pre-existing Conditions that are risk factors for COVID-19 outcomes**

International Statistical Classification of Diseases (ICD)-9-CM and ICD-10-CM codes were mapped to 1866 phecodes, which represent meaningful and interpretable phenotypes (Wei et al., 2017; Wu et al., 2019). For HL and NHL-W, we evaluated the known risk factor phecode categories (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease) controlling for age and sex using the Firth logistic regression model (Firth, 1993; Heinze, 2006):

\[
\logit(\text{outcome}) = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}_\text{group}^2 + \beta_3 \text{sex} + \beta_4 \text{known_risk_factor_phecode_category}
\]

Outcome for Severe was considered Inpatient Severe vs. Inpatient Not Severe; for Inpatient was considered COVID-19 positive Inpatient vs COVID-19 positive Outpatient; and for COVID-19 positive was considered COVID-19 positive vs COVID-19 negative. We used the likelihood ratio test to test for phecode significance (McCullagh and Nelder, 1989) where p<0.05 was considered significant.
To identify additional phecodes that may be COVID-19 risk factors, we calculated the odds ratio of all phecodes correcting for age and sex (Model 1) using the Firth logistic regression model (Firth, 1993; Heinze, 2006), which accounts for phecodes with no counts within an outcome group:

\[
\text{(Model 1) } \text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{phecode}
\]

We used the likelihood ratio test to test for phecode significance (McCullagh and Nelder, 1989). Multiple hypothesis testing correction was performed conservatively using a Bonferroni correction for the number of phecodes tested (Bonferroni et al., 1936). Nominal p-values are reported.

To account for known risk factors (coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, and chronic renal disease), we tested Bonferroni significant phecodes from Model 1 in Model 2 using the Firth logistic regression model as follows:

\[
\text{(Model 2) } \text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{phecode} + \beta_5 \text{coronary_artery_disease} + \beta_6 \text{congestive_heart_failure} + \beta_7 \text{chronic_obstructive_pulmonary_disease} + \beta_8 \text{type_2_diabetes} + \beta_9 \text{hyperlipidemia} + \beta_{10} \text{hypertension} + \beta_{11} \text{obesity} + \beta_{12} \text{chronic_renal_disease}
\]

For Model 1 Bonferroni significant phecodes, we determined if the phecode outcome risk effect was significantly different between HL and NHL-W by evaluating the phecode and HL interaction term in the following Firth logistic regression model (McCullagh and Nelder, 1989):

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{phecode} + \beta_5 \text{Hispanic/Latinx}
\]

For Model 1 Bonferroni significant phecodes, we evaluate if there was an age or sex interaction with these phecode risk factors. We discretized age to greater or less than 65 years old. We considered there to be a significant sex by phecode or age by phecode interaction if there was a significant interaction term in the following Firth logistic regression model (McCullagh and Nelder, 1989):

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{phecode} + \beta_5 \text{sex*phecode}
\]

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{age}_{65} + \beta_2 \text{sex} + \beta_3 \text{phecode} + \beta_4 \text{age}_{65*phecode}
\]

We removed the age^2 term when testing the age > 65 years old and phecode interaction because multiple age terms would be present.

**Pre-existing Conditions that are risk factors for Influenza Hospitalization**

We identified patients in the UCLA DDR from July 1, 2018 to June 30, 2019 with an influenza phecode (Phecode 481). We chose this time period as it was before the COVID-19 pandemic so COVID-19 would not confound results. Influenza inpatient cases were those who had a hospital admission within 14 days of an influenza phecode diagnosis. The controls were those who had an influenza phecode, but were not admitted as inpatients within 14 days. After excluding individuals with missing age, missing sex, or no encounter prior to influenza diagnosis, there were 92 HL influenza inpatients, 859 HL inpatient cases, 92 NHL-W influenza inpatients, and 1785 NHL-W influenza outpatients.

We determined if there was an association of HL ethnicity and inpatient admission using the following Firth logistic regression model (McCullagh and Nelder, 1989).

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{Hispanic/Latinx} + \beta_2 \text{age} + \beta_3 \text{age}^2 + \beta_4 \text{sex}
\]

Outcome was influenza positive Inpatient vs influenza positive Outpatient. Hispanic/Latinx was HL compared to NHL-W. We also corrected for known risk factors using the following Firth logistic regression model (McCullagh and Nelder, 1989).

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{Hispanic/Latinx} + \beta_2 \text{age} + \beta_3 \text{age}^2 + \beta_4 \text{sex} + \beta_5 \text{coronary_artery_disease} + \beta_6 \text{congestive_heart_failure} + \beta_7 \text{chronic_obstructive_pulmonary_disease} + \beta_8 \text{type_2_diabetes} + \beta_9 \text{hyperlipidemia} + \beta_{10} \text{hypertension} + \beta_{11} \text{obesity} + \beta_{12} \text{chronic_renal_disease}
\]

To determine pre-existing conditions associated with influenza inpatient admission for HL and NHL-W, we performed separate analyses for the HL group and the NHL-W group.

We calculated the odds ratio of all phecodes correcting for age and sex (Model 1) using the Firth logistic regression model (McCullagh and Nelder, 1989):

\[
\text{(Model 1) } \text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{phecode}
\]
Outcome was influenza positive Inpatient vs influenza positive Outpatient. We used the likelihood ratio test to test for phecode significance (McCullagh and Nelder, 1989). Multiple hypothesis testing correction was performed conservatively using a Bonferroni correction for the number of phecodes tested (Bonferroni et al., 1936). Nominal p-values are reported.

**Admission Vitals and Labs among COVID-19 positive inpatients**

To determine if COVID-19 positive HL inpatients presented with more abnormal vitals or laboratory values compared to NHL-W inpatients, we compared vitals and labs within +/- one day of admission date between these two groups controlling for age, sex, and known risk factors in the following linear regression model:

\[
\text{Vital or Lab} = \beta_0 + \beta_1 \text{Hispanic/Latinx} + \beta_2 \text{age} + \beta_3 \text{age}^2 + \beta_4 \text{sex} + \beta_5 \text{coronary artery disease} + \beta_6 \text{congestive heart failure} + \beta_7 \text{chronic obstructive pulmonary disease} + \beta_8 \text{type 2 diabetes} + \beta_9 \text{hyperlipidemia} + \beta_{10} \text{hypertension} + \beta_{11} \text{obesity} + \beta_{12} \text{chronic renal disease}
\]

P-values are reported for \( \beta_i \), the HL coefficient

**Extremes of COVID-19 outcome susceptibility or resistance**

We identified HL and NHL-W COVID-19 young individuals with no major comorbidities admitted as an inpatient and COVID-19 older individuals with comorbidities not admitted as an inpatient. We defined COVID-19 young individuals with no major comorbidities admitted as an inpatient as:
- COVID-19 positive
- 18-35 years old
- None of the known risk factor phecode categories: coronary heart disease, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipidemia, hypertension, obesity, chronic renal disease (Table S1)
- Inpatient admission within 14 days of a SARS-CoV-2 positive test.

We defined COVID-19 older individuals with major comorbidities not admitted as an inpatient as:
- COVID-19 positive
- Greater than 70 years old
- At least three of the known risk factors phecodes (Table S1)
- No inpatient admission within 14 days of a SARS-CoV-2 positive test

**Pre-existing Medications Associated with COVID-19**

We investigated prescription of angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), immunosuppressants, oral steroids, oral anticoagulants, and non-steroidal anti-inflammatory drugs (see Table S7 for drugs assigned to medication classes) 90 days prior to SARS-CoV-2 testing. We controlled for age, sex, and known risk factors in the following Firth logistic regression model and used the likelihood ratio test:

\[
\text{logit(outcome)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{coronary artery disease} + \beta_5 \text{congestive heart failure} + \beta_6 \text{chronic obstructive pulmonary disease} + \beta_7 \text{type 2 diabetes} + \beta_8 \text{hyperlipidemia} + \beta_9 \text{hypertension} + \beta_{10} \text{obesity} + \beta_{11} \text{chronic renal disease} + \beta_{12} \text{medication}
\]

Outcome for Severe was considered Inpatient Severe vs. Inpatient Not Severe; for Inpatient was considered COVID-19 positive Inpatient vs COVID-19 positive Outpatient; and for COVID-19 positive was considered COVID-19 positive vs. COVID-19 negative. We performed separate analyses for the HL group and the NHL-W group.

We investigated if medication prescription durations < 1 year or ≥ 1 year compared to no prescription were associated with COVID-19 inpatient admission risk. Medication duration was defined for a medication class from the first prescription to the most recent prescription within 90 days of SARS-CoV-2 testing. We controlled for age, sex, and known risk factors in the following Firth logistic regression model and used the likelihood ratio test:

\[
\text{logit(inpatient admission)} = \beta_0 + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{sex} + \beta_4 \text{coronary artery disease} + \beta_5 \text{congestive heart failure} + \beta_6 \text{chronic obstructive pulmonary disease} + \beta_7 \text{type 2 diabetes} + \beta_8 \text{hyperlipidemia} + \beta_9 \text{hypertension} + \beta_{10} \text{obesity} + \beta_{11} \text{chronic renal disease} + \beta_{12} \text{medication_<1yr} + \beta_{13} \text{medication_≥1yr}
\]

**Supplemental References**

Bonferroni, C.E., Bonferroni, C., and Bonferroni, C.E. (1936). *Teoria statistica delle classi e calcolo delle probabilità*.

Firth, D. (1993). Bias reduction of maximum likelihood estimates. Biometrika 27–38.

Fisher, R.A. (1922). On the interpretation of \( \chi^2 \) from contingency tables, and the calculation of \( P \). Journal of the Royal Statistical Society 85, 87–94.
Goyal, P., Choi, J.J., Pinheiro, L.C., Schenck, E.J., Chen, R., Jabri, A., Satlin, M.J., Campion, T.R., Nahid, M., Ringel, J.B., et al. (2020). Clinical Characteristics of Covid-19 in New York City. N. Engl. J. Med. 382, 2372–2374.

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cerde, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020a). Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323, 1574–1581.

Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, A., et al. (2020b). Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 180, 1345–1355.

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D.S.C., et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382, 1708–1720.

Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., et al. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146, 110–118.

McCullagh, P., and Nelder, J.A. (1989). Generalized Linear Models (Boca Raton: Chapman and Hall/CRC).

UC Health (2019). University of California Medical Centers Report. Accessed Dec 8, 2020. https://regents.universityofcalifornia.edu/regmeet/nov19/f5attach3.pdf

UCLA Health (2020). About Us: UCLA Health, Los Angeles, CA. Accessed Dec 8, 2020. https://www.uclahealth.org/about-us

U.S. Census Bureau (2018). U.S. Census Bureau QuickFacts: Los Angeles County, California. https://www.census.gov/quickfacts/losangelescountycalifornia

Wei, W.-Q., Bastarache, L.A., Carroll, R.J., Marlo, J.E., Osterman, T.J., Gamazon, E.R., Cox, N.J., Roden, D.M., and Denny, J.C. (2017). Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS ONE 12, e0175508.

Wu, P., Gifford, A., Meng, X., Li, X., Campbell, H., Varley, T., Zhao, J., Carroll, R., Bastarache, L., Denny, J.C., et al. (2019). Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med Inform 7, e14325.

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., and Zhou, Y. (2020). Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054–1062.

Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., et al. (2020). Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 31, 1068-1077.e3.